Comparison 4.
Benralizumab (SC) versus placebo
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---|---|---|---|---|
| 1 Rate of exacerbations requiring systemic corticosteroids | 3 | 2456 | Rate Ratio (Fixed, 95% CI) | 0.62 [0.55, 0.70] |
| 1.1 Eosinophilic | 3 | 1698 | Rate Ratio (Fixed, 95% CI) | 0.59 [0.51, 0.68] |
| 1.2 Non‐eosinophilic | 2 | 758 | Rate Ratio (Fixed, 95% CI) | 0.69 [0.56, 0.85] |
| 2 Rate of exacerbations requiring emergency department treatment or admission | 2 | 1537 | Rate Ratio (Fixed, 95% CI) | 0.68 [0.47, 0.98] |
| 2.1 Eosinophilic | 2 | 1537 | Rate Ratio (Fixed, 95% CI) | 0.68 [0.47, 0.98] |
| 3 Health‐related quality of life (AQLQ mean difference) | 3 | 1541 | Mean Difference (Fixed, 95% CI) | 0.23 [0.11, 0.35] |
| 3.1 Eosinophilic | 3 | 1541 | Mean Difference (Fixed, 95% CI) | 0.23 [0.11, 0.35] |
| 4 Health‐related quality of life (ACQ mean difference) | 3 | 2359 | Mean Difference (Fixed, 95% CI) | ‐0.20 [‐0.29, ‐0.11] |
| 4.1 Eosinophilic | 3 | 1604 | Mean Difference (Fixed, 95% CI) | ‐0.23 [‐0.34, ‐0.12] |
| 4.2 Non‐eosinophilic | 2 | 755 | Mean Difference (Fixed, 95% CI) | ‐0.14 [‐0.30, 0.02] |
| 5 Pre‐bronchodilator FEV1 (litres) | 3 | 2355 | Mean Difference (Fixed, 95% CI) | 0.10 [0.05, 0.14] |
| 5.1 Eosinophilic | 3 | 1617 | Mean Difference (Fixed, 95% CI) | 0.13 [0.08, 0.19] |
| 5.2 Non‐eosinophilic | 2 | 738 | Mean Difference (Fixed, 95% CI) | 0.03 [‐0.03, 0.10] |
| 6 Serious adverse events | 4 | 2648 | Risk Ratio (M‐H, Random, 95% CI) | 0.81 [0.66, 1.01] |
| 6.1 Eosinophilic | 2 | 1537 | Risk Ratio (M‐H, Random, 95% CI) | 0.80 [0.60, 1.06] |
| 6.2 Non‐eosinophilic | 2 | 758 | Risk Ratio (M‐H, Random, 95% CI) | 0.85 [0.57, 1.27] |
| 6.3 Eosinophil status unknown | 2 | 353 | Risk Ratio (M‐H, Random, 95% CI) | 0.75 [0.37, 1.51] |
| 7 Adverse events leading to discontinuation | 3 | 2597 | Risk Ratio (M‐H, Random, 95% CI) | 2.15 [1.02, 4.57] |
| 7.1 Eosinophilic | 2 | 1537 | Risk Ratio (M‐H, Random, 95% CI) | 2.70 [0.86, 8.49] |
| 7.2 Non‐eosinophilic | 2 | 758 | Risk Ratio (M‐H, Random, 95% CI) | 1.81 [0.54, 6.05] |
| 7.3 Eosinophil status unknown | 1 | 302 | Risk Ratio (M‐H, Random, 95% CI) | 1.82 [0.31, 10.69] |
| 8 Serum eosinophil level (% change from baseline) | 2 | 2295 | Mean Difference (Fixed, 95% CI) | ‐104.74 [‐116.12, ‐93.35] |
| 8.1 Eosinophilic | 2 | 1537 | Mean Difference (Fixed, 95% CI) | ‐101.74 [‐113.27, ‐90.21] |
| 8.2 Non‐eosinophilic | 2 | 758 | Mean Difference (Fixed, 95% CI) | ‐216.81 [‐287.35, ‐146.28] |